Astegolimab for chronic obstructive pulmonary disease with frequent exacerbations: pooled analysis of the ALIENTO and ARNASA trials.
Jadwiga A Wedzicha, Àlvar Agustí, Christopher E Brightling et al.
✦ AI-curated · Sources linked
In 30 seconds
This pooled analysis of the ALIENTO and ARNASA trials evaluated the efficacy of astegolimab, an anti-ST2 monoclonal antibody, in patients with chronic obstructive pulmonary disease (COPD) experiencing frequent exacerbations. The randomized controlled trial included 2682 participants and found that astegolimab reduced the annualized rate of moderate/severe exacerbations by 15% for the Q2W dosing and 12% for the Q4W dosing compared to placebo.
Key findings
- Astegolimab Q2W reduced moderate/severe exacerbations by 15% (rate ratio, 0.85; P=0.0077).
- Astegolimab Q4W reduced moderate/severe exacerbations by 12% (rate ratio, 0.88; P=0.0265).
- A nominally significant reduction in severe exacerbations was observed with Q2W dosing (rate ratio, 0.68; P=0.0028).
- Astegolimab was well tolerated among participants.
Why it matters
The findings suggest that astegolimab may provide a new therapeutic option for managing frequent exacerbations in COPD, potentially improving patient outcomes and reducing healthcare burdens associated with exacerbation events.